Biobeat secured a $50M Series B financing to advance commercialization of its cuffless ambulatory blood pressure monitor.
Biobeat is revolutionizing care with its groundbreaking advancements in diagnosis and management of hypertension through a cuffless, ambulatory blood pressure monitoring system
Biobeat is revolutionizing care with its groundbreaking advancements in diagnosis and management of hypertension through a cuffless, ambulatory blood pressure monitoring system.